To review the published clinical studies reporting volume of distribution for
aminoglycosides in patient population subgroups. Controversies in methods used are
discussed.
DATA SOURCES:
National Library of Medicine Medlars, searched using MEDLINE.
STUDY SELECTION:
Published articles primarily relating to pharmacokinetic properties of aminoglycosides
in specific adult patient subgroups published within the past 20 years were included.
Pediatric studies were excluded.
DATA EXTRACTION:
The methodology, assay technique, and results from clinical studies reporting
aminoglycoside volume of distribution were evaluated.
DATA SYNTHESIS:
Clinical studies reporting aminoglycoside volume of distribution subgroups, including
the methods by which their results were derived, are tabulated.
CONCLUSIONS:
The expected aminoglycoside volume of distribution can vary, depending on a patient's
clinical presentation. Data presented will allow a more refined initial estimation of
volumes of distribution, which may facilitate the achievement of desired aminoglycoside
serum concentrations.
Get full access to this article
View all access options for this article.
References
1.
TownsendPLFinkMPSteinKLMurphySG. Aminoglycoside pharmacokinetics: Dosage
requirements and nephrotoxicity in trauma patients. Crit Care
Med1989; 17:
154–7.
2.
MooreRSmithCLiethmanP. Association of aminoglycoside plasma levels with
therapeutic outcome in gram-negative pneumonia. Am J
Med1984; 77:
657–62.
3.
MarikPE. Aminoglycoside volume of distribution and illness
severity in critically ill septic patients. Anaesth Intensive
Care1993; 21:
172–3.
4.
MannHJFuhsDNAwangRNdemoFACerraFB. Altered aminoglycoside pharmacokinetics in
critically ill patients with sepsis. Clin Pharm1987; 6:
148–53.
5.
TriginerCIzquierdoIFernandezRRelloJTorrentJBenitaSGentamicin volume of distribution in critically ill septic
patients. Intensive Care Med1990; 16:
303–6.
6.
OparaojiECCornwellEEHekmatECheongRLAdirJSSiramS. Aminoglycoside volume of distribution in
postoperative patients with septic shock. Clin Pharm1992; 12:
131–4.
7.
ZaskeDECipolleRJStrateRJ. Gentamicin dosage requirements: Wide interpatient
variations in 242 surgery patients with normal renal function.
Surgery1980; 87:
164–9.
8.
TriginerCIzquierdoIFernandezRTorrentJBenitoSNetAChanges in gentamicin pharmacokinetics profiles induced by mechanical
ventilation. Eur J Clin Pharmacol1991; 40:
297–302.
9.
SawchukRJZaskeDE. Pharmacokinetics of dosing regimens which utilize
multiple intravenous infusions: Gentamicin in burn patients. J
Pharmacokinet Biopharm1976; 4:
183–95.
KlothDDTegtmzierBRKongCAkahoshiMPLeachSHBeattyJDAltered gentamicin pharmacokinetics during the perioperative
period. Clin Pharm1985; 4:
182–5.
12.
GillMAKernJW. Altered gentamicin distribution in ascitic
patients. Am J Hosp Pharm1979; 36:
1704–6.
13.
KaojarernSArkaravichienWIndraprasitSPummanguraC. Dosing regimen of gentamicin during intermittent
peritoneal dialysis. J Clin Pharmacol1989; 29:
140–3.
14.
GoetzDRPancorboSHoagSBloomP. Prediction of serum gentamicin concentration in
patients undergoing hemodialysis. Am J Hosp Pharm1980; 37:
1077–82.
15.
CarrMRDickSPBordleyJBertinoJS. Gentamicin dosing requirements in patients with
acute pancreatitis. Surgery1988; 103:
533–7.
16.
EtzelJVNafzigerANBertinoJS. Variation in the pharmacokinetics of gentamicin
and tobramycin in patients with pleural effusions and hypoalbuminemia.
Antimicrob Agents Chemother1992; 36:
679–81.
17.
BauerLABlouinRAGriffenWORecordKEBeuRM. Amikacin pharmacokinetics in morbidly obese
patients. Am J Hosp Pharm1980; 37:
519–22.
18.
SchwartzSNPaxinGJLyonJAHoMPasculleAW. A controlled investigation of the
pharmacokinetics of gentamicin and tobramycin in obese subjects.
J Infect Dis1978; 138:
499–505.
19.
TointonMMJobMLPeltierTTMurphyJEWardES. Alteration in aminoglycoside volume of
distribution in patients below ideal body weight. Clin
Pharm1987; 6:
160–2.
20.
SegalJLGrayDRGordonSK. Pharmacokinetics of gentamicin in patients with
spinal cord injury. Clin Pharm1984; 3:
418–20.
21.
ZaskeDIrvinePStrandLMStrateRGCipolleRGRotschaferJ. Wide interpatient variations in gentamicin dose
requirements for geriatric patients. JAMA1982; 248:
3122–6.
22.
LongleyJMPittmanDGNewbyDF. Altered aminoglycoside volume of distribution in
patients with acquired immunodeficiency syndrome. Clin
Pharm1991; 10:
784–6.
23.
KatzRBLawsonLAJohnsonNESchechterLN. Aminoglycoside pharmacokinetics in patients with
AIDS. J Pharm Technol1993; 9:
14–7.
24.
ZarowitzBJPillaAMPopovichJ. Expanded gentamicin volume of distribution in
patients with indicators of malnutrition. Clin Pharm1990; 9:
40–4.
25.
HigaGMMurrayWE. Alteration in aminoglycoside pharmacokinetics in
patients with cancer. Clin Pharm1987; 6:
963–6.
26.
DavisRLLehmannOStidleyCANeidhartJ. Amikacin pharmacokinetics in patients receiving
high-dose cancer chemotherapy. Antimicrob Agents
Chemother1991; 35:
944–7.
27.
BertinoJSBookerLAFranckPRybickiB. Gentamicin pharmacokinetics in patients with
malignancies. Antimicrob Agents Chemother1991; 35:
1501–3.
28.
GillMAOkamotoMPNakahiroRKChinAInagakiKSclarD. Pharmacokinetic parameters for aminoglycosides in
cholecystitis patients. Ther Drug Monit1992; 14:
107–11.
29.
ZaskeDECipolleRJRotschaferJCSolemLDMosierNRStrateRG. Gentamicin pharmacokinetics in 1640 patients:
Method for control of serum concentrations. Antimicrob Agents
Chemother1982; 21:
407–11.
BergMJLantzRKSchoenwaldRDClarkeMISchotteliusOD. Optimization of pharmacokinetic monitoring: I.
Linear pharmacokinetics. Ther Drug Monit1983; 5:
379–87.
32.
RotschaferJCMorlockCStrandLCrossleyK. Comparison of radioimmunoassay methods in
determining gentamicin pharmacokinetic parameters and dosages.
Antimicrob Agents Chemother1982; 22:
648–51.
33.
BoyceEGLawsonLAGibsonGANachamkinI. Comparison of gentamicin immunoassays using
univariate and multivariate analysis. Ther Drug Monit1989; 11:
97–104.
34.
GotelliGWinterMMitchellM. Liquid-chromatograph analysis for tobramycin in
samples giving discrepant results by enzyme immunoassay and fluoroimmunoassay
(letter). Clin Chem1984; 30: 110.
35.
BoyceEGPughCB. Computer-simulated effect of errors in infusion
duration and blood sampling times on pharmacokinetic calculations for
gentamicin. Clin Pharm1989; 8:
48–53.
36.
FransenTRRitchPSQuebbemanEJ. Aminoglycoside serum concentration sampling via a
central venous catheter: A potential source of error. JPEN J
Parenter Enteral Nutr1987; 51:
77–9.
37.
TindulaRJAmbrosePJHarralsonAF. Aminoglycoside inactivation by penicillins and
cephalosporins and its impact on drug-level monitoring. Drug
Intell Clin Pharm1983; 17:
906–8.
ChrystynH. Validation of the use of Bayesian analysis in the
optimization of gentamicin therapy from the commencement of dosing.
Drug Intell Clin Pharm1988; 22:
49–53.
40.
McClellanSDFarringerJA. Bayesian forecasting of aminoglycoside dosing
requirements in obese patients; influence of subpopulation versus general population
pharmacokinetic parameters as the internal estimates. Ther Drug
Monit1989; 11:
431–6.
